Amgen Highlights Pipeline at TD Cowen Conference
THOUSAND OAKS, Calif., February 24, 2026 Amgen announced it will present at the 46th Annual TD Cowen Health Care...
Alzheimer’s Disease Animal Health Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cell Therapy cGxP cGxP compliance Clinical-Stage Biotech Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy GMP compliance Immuno-Oncology immunology Immunotherapy Johnson & Johnson Medical Devices MedTech medtech innovation Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine Regulatory Affairs regulatory approval regulatory compliance Sanofi targeted therapy
THOUSAND OAKS, Calif., February 24, 2026 Amgen announced it will present at the 46th Annual TD Cowen Health Care...
NEW YORK, Feb. 24, 2026 — Bristol Myers Squibb announced its participation in the upcoming TD Cowen 46th Annual...
RESEARCH TRIANGLE PARK, N.C., and NOTTINGHAM, U.K., Feb. 16, 2026 — Global contract research organization Worldwide Clinical Trials has...
TAINAN, Taiwan, Feb. 9, 2026 — MerryLife Biomedical Inc. announced positive Phase 1 clinical findings for TML-6, its investigational...
Houston, Texas | January 2026 — HeartX, a leading cardiovascular innovation accelerator, has officially opened applications for its 2026...
NASHVILLE, Tenn., Feb. 4, 2026 —Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has granted Fast...
AUSTIN, Texas, Feb. 2, 2026 — Early-stage investor Santé Ventures announced the successful close of its fifth and largest...
London, United Kingdom | January 29, 2026 — LifeArc Ventures, the venture capital arm of medical research organization LifeArc,...
MONTPELLIER, France | January 28, 2026 — Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, announced a...
Hong Kong, January 26, 2026 — Ascletis Pharma continued progress in the clinical development of ASC30, its investigational oral...
